Food Allergy Treatment Market By Treatment Type (Preventive Anti-IgE Biologics, Injectable Epinephrine Auto-Injectors, Intranasal Epinephrine, Peanut Oral Immunotherapy, Antihistamines, Corticosteroids, and Other Adjunctive Medicines); By Patient Group (Pediatric and Adult); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Specialty Pharmacies, and Online Pharmacies); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Food Allergy Treatment Market: Preventive Biologics and Needle-Free Epinephrine Reshape Commercial Demand

The Global Food Allergy Treatment Market was valued at USD 7.16 billion in 2025 and is projected to reach USD 12.5 billion by 2032, growing at a CAGR of 8.31%, according to Strategic Market Research.

 

Food allergy treatment is moving beyond allergen avoidance and emergency response. Recurring preventive biologics, differentiated epinephrine delivery systems, and allergen-specific immunotherapy now form separate pharmaceutical segments with different pricing, access, administration, and retention requirements.

 

Diagnosed Prevalence Provides a Large but Heavily Filtered Patient Pool

CDC data show that 6.7% of U.S. adults and 5.3% of children had a diagnosed food allergy in 2024. Pediatric prevalence increased from 3.9% among children aged 0–5 to 6.9% among adolescents aged 12–17. Applying the overall rates to U.S. population estimates produces an analytical upper-bound estimate of approximately 21.8 million diagnosed people, including about 17.9 million adults and 3.9 million children.

Reported diagnosis does not equal confirmed IgE-mediated food allergy or pharmaceutical eligibility. Positive skin-prick and blood tests may identify sensitization without proving that exposure will cause a clinically relevant reaction. Allergists also consider reaction history, allergen type, comorbid asthma, patient age, accidental-exposure risk, treatment preference, and the feasibility of continued monitoring.

Supervised oral food challenges help confirm or exclude allergy when clinical history and testing remain inconclusive. Accurate diagnosis prevents unnecessary dietary restrictions, particularly among children, and narrows the patient pool to people who may benefit from rescue prescriptions, biologics, or immunotherapy.

 

Biologics and Emergency Epinephrine Account for Most Disclosed Sales

Combined disclosed Xolair sales reached approximately USD 5.422 billion in 2025. Roche’s U.S. business recorded USD 3.699 billion, while Novartis reported USD 1.723 billion outside the United States. Both figures cover all Xolair indications, including asthma, chronic urticaria, nasal polyps, and food allergy. They must not be presented as food-allergy treatment revenue.

Roche reported that more than 100,000 food-allergy patients received Xolair during the launch period. The company did not disclose food-allergy-specific revenue, injection volume, average treatment duration, or discontinuation rates. Patient starts confirm meaningful adoption, but they do not indicate how many patients remained on treatment throughout 2025.

Viatris reported USD 469.7 million in global EpiPen Auto-Injector sales in 2025, compared with USD 392.0 million in 2024 and USD 442.2 million in 2023. 

ARS Pharmaceuticals generated USD 72.2 million in U.S. neffy net product revenue in 2025, up from USD 7.3 million in 2024. Total company revenue of USD 84.3 million also included collaboration and supply payments and therefore overstates nasal-spray product sales.

 

Xolair Established the Premium Recurring-Treatment Pathway

The FDA approved Xolair in February 2024 for adults and children aged one year and older with IgE-mediated food allergy. Treatment reduces the risk of reactions, including anaphylaxis, after accidental exposure to one or more foods. Patients must continue avoiding confirmed allergens and carrying emergency epinephrine because omalizumab does not treat an acute reaction.

Food-allergy dosing ranges from 75 mg to 600 mg every two or four weeks, based on pretreatment IgE and body weight. Two-week dosing creates approximately 26 treatment occasions annually, while four-week dosing creates about 13. Higher doses may require multiple injections during one treatment occasion.

Reported patient starts cannot be multiplied by 13 or 26 to estimate national injection volume. Patients entered treatment at different points during the year, dosing frequencies varied, and some patients discontinued or moved to home administration.

Initial treatment begins in a healthcare setting equipped to manage anaphylaxis. Selected patients may later self-administer or receive treatment from a caregiver after completing supervised doses without a serious reaction. Home administration reduces clinic visits but increases the importance of specialty-pharmacy fulfilment, patient training, storage, adherence, and benefit verification.

Injection-site reactions occurred in 15.5% of Xolair-treated pediatric patients in the food-allergy trial, compared with 10.9% receiving placebo. Fever occurred in 6.4% versus 3.6%. Xolair-associated anaphylaxis was reported in approximately 0.1% of clinical-trial patients and at least 0.2% in older postmarketing estimates across indications. Reactions have occurred after the first dose and after more than one year of treatment, requiring continued patient education and monitoring.

 

Intranasal Epinephrine Introduces Format-Based Competition

Neffy created the first FDA-approved needle-free epinephrine pathway. The U.S. indication covers adults and children weighing at least 15 kilograms. Commercial differentiation rests on portability, ease of administration, and reduced needle hesitation rather than a new active drug.

Common adverse effects include nasal discomfort, runny nose, throat irritation, headache, dizziness, nausea, and vomiting. Children may also experience congestion, sneezing, nasal dryness, nosebleed, fatigue, or jitteriness. Most local reactions require observation rather than additional treatment.

U.S. revenue growth indicates demand for an alternative to auto-injectors, but long-term switching will depend on formulary coverage, prescriber confidence, patient training, repeat-dose instructions, and real-world carrying behaviour.

European and Australian authorizations extend the addressable geography. ARS has not disclosed complete 2025 European retail or net sales, and royalty or partnership receipts should not be presented as end-market product revenue.

 

Palforzia’s July 2026 Discontinuation Narrows the Commercial OIT Market

Palforzia is the only FDA-approved food-specific oral immunotherapy covered in this analysis, but its commercialization will be discontinued from July 31, 2026. Children aged 1–17 with confirmed peanut allergy may initiate treatment until access closes, subject to specialist assessment and product availability. The manufacturer stated that the withdrawal is unrelated to Palforzia’s safety, quality, or efficacy. The decision removes the only standardized pharmaceutical OIT product from the market and limits future treatment largely to specialist-developed, noncommercial protocols.

Children aged 1–3 require an initial escalation visit followed by 12 supervised up-dosing levels, producing at least 13 clinic visits before maintenance. Patients aged 4–17 require one initial visit and 11 up-dosing levels, or at least 12 supervised visits. The first dose at each new level is administered in a healthcare setting with at least 60 minutes of observation, followed by daily maintenance at home.

Among patients aged 4–17, anaphylaxis occurred in 9.4% during escalation and up-dosing and 8.7% during maintenance, compared with 3.8% and 1.7% with placebo. Epinephrine was used by 10.4% during escalation and up-dosing and 7.7% during maintenance. Allergic reactions may require treatment interruption, dose reduction, slower escalation, or permanent discontinuation, increasing the clinical-support burden for allergy practices.

Twelve Palforzia-treated trial participants developed biopsy-confirmed eosinophilic esophagitis. All improved symptomatically after stopping treatment. Follow-up biopsies showed complete resolution in six patients and improvement in two. Persistent swallowing difficulty, reflux, vomiting, chest pain, or abdominal pain can therefore reduce treatment persistence and add gastroenterology assessment and monitoring costs.

Specialist practices may continue offering noncommercial food OIT protocols after Palforzia is withdrawn. National activity remains difficult to quantify because initial escalation may be billed under ingestion-challenge codes, while later up-dosing appointments are often recorded as standard evaluation-and-management visits.

 

Impactful Treatment Segments

Preventive Biologics

Anti-IgE biologics generate the highest recurring revenue per treated patient through repeated administration and specialty reimbursement. Multi-food protection broadens their use beyond allergen-specific programs. High cost, prior authorization, weight- and IgE-based dosing, injection frequency, and uncertain treatment duration restrict adoption. Biosimilars and longer-interval antibodies may increase payer leverage and reduce the pricing advantage of established brands.

Injectable Epinephrine

Auto-injectors retain broad physician familiarity, established pharmacy distribution, and a large prescription base. Demand comes from new diagnoses, expiry replacement, school requirements, and prescriptions for multiple locations. Suppliers compete on price, device reliability, formulary access, training, and ease of use. Sales remain a poor measure of emergency utilization because most devices are never administered.

Intranasal Epinephrine

Nasal epinephrine addresses needle anxiety, administration hesitation, and portability barriers. Early U.S. sales indicate willingness to adopt a differentiated delivery system. Wider use will depend on reimbursement, prescribing confidence, patient education, second-dose protocols, and evidence that easier administration improves product carrying and timely treatment.

Peanut Oral Immunotherapy

Peanut OIT requires supervised escalation, frequent clinic appointments, daily adherence, continued avoidance, and emergency preparedness. Palforzia’s withdrawal reduces standardized pharmaceutical availability despite continued clinical demand. Office-based protocols may preserve access, but their activity is harder to measure through product sales, prescription databases, or national procedure counts.

Pediatric Treatment

Children account for a large share of specialist consultations, testing, rescue prescriptions, immunotherapy, and biologic eligibility. Family acceptance, age or weight criteria, school preparedness, and access to pediatric allergists influence treatment initiation. Families may also require several rescue devices for home, school, travel, and caregivers, increasing replacement demand.

 

Regional Access Reflects Diagnostic Accuracy, Reimbursement, and Allergen Patterns

The United States has the strongest commercial base for preventive biologics and differentiated rescue products. More than 26 million adults and 4 million children are estimated to live with food allergies, while physician-confirmed prevalence reaches about 10.8% among adults and 5.8%–8% among children. Self-reported allergy remains much higher than clinically confirmed disease: around 19% of adults believe they have a food allergy, but testing confirms fewer than half of these cases. This diagnostic gap reduces the population eligible for high-cost biologics and allergen-specific treatment. Among confirmed patients, up to 51% of adults report a severe reaction and 38% have made at least one food-allergy-related emergency department visit, supporting continued demand for prescription epinephrine and preventive protection.

Europe combines a substantial patient population with fragmented access. Self-reported food allergy reaches as high as 19.9%, while medically confirmed prevalence is estimated at approximately 0.8%–5% among adults. Northern European prevalence is generally higher because pollen-related cross-reactivity increases reactions to plant foods, while milk, egg, fish, and nuts account for most pediatric reactions. Xolair does not currently carry an EMA food-allergy indication, limiting direct European biologic adoption, whereas Eurneffy provides a common regulatory platform for nasal epinephrine. Country-level reimbursement, prescribing rules, and pharmacy distribution will determine commercial uptake.

Global food-allergy prevalence is estimated at 1%–10%, representing more than 220 million and potentially around 250 million people. Commercial strategies must account for regional allergen differences rather than applying a North American treatment model universally. Peanut and egg are prominent in North America and Northern Europe, fish and shellfish are more important across Asia, and lentil and chickpea allergies are more relevant in India and Mediterranean populations. Australia remains an attractive pediatric market, while limited specialist capacity, weak biologic reimbursement, and out-of-pocket payment keep emergency treatment and diagnostic services ahead of premium preventive therapies across many emerging markets.

 

Long-Acting Biologics Could Reduce Administration Burden

GSK completed its USD 2.2 billion acquisition of RAPT Therapeutics in March 2026, adding ozureprubart, a Phase IIb long-acting anti-IgE antibody. The candidate is being studied with an intended dosing interval of approximately 12 weeks, compared with every two or four weeks for current omalizumab treatment. GSK has also indicated that the medicine may cover some patients who fall outside existing omalizumab dosing criteria.

Phase IIb results are expected in 2027. Approval remains dependent on efficacy, safety, eligible-patient breadth, manufacturing, and regulatory review. A longer interval could reduce treatment visits, improve persistence, and strengthen payer value arguments, but only if protection remains comparable with established anti-IgE therapy.

 

Market Outlook

Preventive anti-IgE biologics account for the market’s premium recurring-treatment pathway, while emergency epinephrine serves the broadest prescription population. Intranasal delivery has created meaningful competition around administration format, and Palforzia’s withdrawal has weakened the standardized oral-immunotherapy segment.

Revenue growth depends on movement through the treatment funnel rather than prevalence alone. Confirmed diagnosis, specialist access, payer authorization, treatment initiation, safety management, adherence, and persistence determine the number of commercially active patients.

 

Food Allergy Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 7.16 Billion
Revenue Forecast in 2032	USD 12.5 Billion
Overall Growth Rate	CAGR of 8.31% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Patient Group, By Distribution Channel, By Geography
By Treatment Type	Preventive Anti-IgE Biologics, Injectable Epinephrine Auto-Injectors, Intranasal Epinephrine, Peanut Oral Immunotherapy, Antihistamines, Corticosteroids, Other Adjunctive Medicines
By Patient Group	Pediatric, Adult
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies and Drug Stores, Specialty Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising diagnosed food-allergy prevalence and severe-reaction risk Expanding adoption of preventive anti-IgE biologics Commercialization of needle-free epinephrine
Customization Option	Available upon request